RareResearch.AI
← Back to atlas

R685P

Category 3/4 — Most DruggablePathogenicLumenal · predictedσ-1 candidateEditorial
ArginineProline at position 685 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

Arginine → Proline at position 685 in wolframin's C-terminal lumenal domain. ClinVar Pathogenic, associated with rare genetic deafness. AlphaMissense 0.954, DynaMut2 ΔΔG +0.33 kcal/mol — a STABILIZING substitution. A charge-loss-plus-helix-break variant.

Interactive 3D Structure

Wild-type reference
Wild-type R685 — hydrogen bond to L689
Fullscreen ↗
DynaMut2 mutant · R685P
Mutant P685 — hydrogen bond to N682 lost (5 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

5 lost2 gained3 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondN682Lost
Hydrogen bondI688Lost
Hydrogen bondL689L689Preserved
Polar contactN682N682Preserved
Polar contactM683Lost
Polar contactI688Lost
Polar contactL689L689Preserved
Van der WaalsN682Gained
Van der WaalsM683Lost
HydrophobicN682Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
0.33kcal/mol
Stabilising — mild
AlphaMissense
0.954
LPath
AlphaFold pLDDT
90
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationPathogenic
Review statuscriteria provided, single submitter
Associated conditionsRare genetic deafness
InheritanceDocumented in association with rare genetic deafness. AD-leaning presentation pattern likely.
Population frequency (gnomAD v4)Ultra-rare · AF 0.000068%
cDNA changec.2054G>C
ClinVar accessionVCV000045446
Last evaluated2012/02/28 00:00

Observed at very low frequency in gnomAD.

Structural Context

Position 685 sits in wolframin's C-terminal lumenal domain. The AlphaFold model places R685 within 5 Å of THR686 (2.5 Å), ALA684 (2.5 Å — the partner residue in the A684T atlas card), ASN682 (3.5 Å), MET683 (4.3 Å), and GLN687 (4.4 Å). The wild-type arginine's long, positively-charged side chain likely makes H-bond contacts with the nearby polar residues (N682, T686, Q687).

Replacing arginine with proline at 685 removes the long side chain and introduces a rigid ring-locked residue. The H-bond network the wild-type R685 maintained is gone; the local backbone gains a forced kink from the proline. The DynaMut2 ΔΔG of +0.33 (stabilising) reflects that the tighter local packing achievable with proline outweighs the lost H-bonding in pure energetic terms.

Yet the variant is pathogenic — AlphaMissense 0.954, ClinVar Pathogenic, associated with rare genetic deafness. The pathogenic mechanism is functional: the lost R685 H-bond network is required for wolframin's lumenal function (likely partner protein recognition), even though the fold accommodates the substitution structurally.

Notably, A684T sits at the adjacent position with its own Atlas card — a second variant in the same microregion. Both R685P and A684T perturb the M683-A684-R685-T686 loop geometry, just from different sides.

Amino-acid chemistry
Arginine (R) → Proline (P) — a large, positively-charged guanidinium-bearing residue replaced by a rigid, helix-breaking residue. Loss of charge and side chain volume; introduction of backbone constraint.
Position in the protein
C-terminal lumenal domain · position 685 in the ER lumen with high AlphaFold confidence (pLDDT 90).

Druggability Assessment

Category 4 — Stable Fold, Function Disrupted. ΔΔG = +0.33 kcal/mol — actively stabilising. AlphaMissense 0.954 + clinical evidence confirm pathogenicity.

The mechanism is functional rather than structural: lost R685 H-bond network with N682, T686, Q687, plus introduction of a backbone kink from proline. Drug discovery here aims at the functional contact, not at fold rescue.

Combined with A684T (Atlas card adjacent), drug discovery in the 683-687 microregion has two convergent variant targets.

Why this matters

R685P is another Atlas variant where ΔΔG is positive (stabilising) but the variant is unambiguously pathogenic — joining T361I, L402P in this class. These variants are invisible to ΔΔG-only analysis but clearly picked up by AlphaMissense and clinical evidence. They are exactly the variants the Atlas's dual-metric framing was designed to surface.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the R685P PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download R685P PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal
Natural variant685685 · in DFNA6; dbSNP:rs142668478